Prescribing information

 

   

SANDOSTATIN LAR has a well-established adverse event profile1,2

Adverse events are predictable and manageable1

During SANDOSTATIN LAR treatment, the most common adverse reactions reported include:1

Chart detailing the most common adverse reactions reported during SANDOSTATIN LAR treatment

 

Adverse drug reactions reported in clinical studies1

Adverse drug reactions Very common (≥1/10) Common (≥1/100) Uncommon (≥1/1,000, <1/100)
Gastrointestinal disorders Diarrhoea, abdominal pain,nausea, constipation, flatulence Dyspepsia, vomiting, abdominal bloating, steatorrhoea, loose stools, discolouration of faeces
Nervous system disorders Headache Dizziness
Endocrine disorders Hyperthyroidism, thyroid disorder
Hepatobiliary disorders Cholelithiasis Cholecystitis, biliary sludge, hyperbilirubinaemia
Metabolism and nutrition disorders Hyper glycaemia Hypoglycaemia, impaired glucosetolerance, anorexia Dehydration
General disorders and administration site conditions Injection site reactions Asthenia
Investigations Elevated transaminase levels
Skin subcutaneous tissue disorders Pruritus, rash, alopecia
Respiratory disorders Dyspnoea
Cardiac disorders Bradycardia Tachycardia

For more information, refer to the SANDOSTATIN® LAR® (octreotide acetate) Summary of Product Characteristics

 

References

  1. SANDOSTATIN® LAR®. Summary of Product Characteristics. December 2020.
  2. Rinke A, et al. J Clin Oncol. 2009;27:4656–4663.
Rate this content: 
No votes yet
UK | May 2021 | 104734
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk[email protected]